For UK pharmaceutical and life sciences leaders

Your KOL programme isn't generating the clinical advocacy you need

KOL investment is substantial. The return on that investment is rarely measured. The pharma companies generating real clinical advocacy from their KOL programmes have a structured engagement model, not just relationship management.